December 01
Having been the responsibility of the European Commission's DG Enterprise and Industry for many years, pharmaceutical policy in the EU is to be switched to the Health and Consumer Policy directorate, DG Sanco, at the beginning of 2010.
Responsibility for the European Medicines Agency (EMEA, which will now be abbreviated as EMA) will be included in the portfolio of the new Health Commissioner John Dalli, who currently serves as the Minister for Social Policy in Malta.
The switch has been welcomed by consumer associations across the board - from the European Public Health Alliance to the Confederation of Family Organisations in the European Union - and Members of the European Parliament (MEPs), who have hailed the move as "a sustained and integrated approach to health policy". Campaigners for the switch have long asserted that responsibility for pharmaceuticals in the EU should lie with the health division, as it does in all the individual member states.
However, Pharm Exec Europe's Brussels correspondent, Reflector, highlighted a point of concern. "Bringing the industry into the ambit of health and consumer affairs will leave it exposed to - and largely undefended from - the views of policymakers," he said. "They focus principally on medicines as a social good, and tend to ignore the industrial imperatives that underlie the exercise of making medicines available."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.